BioPharmSignal logoBioPharmSignal

Biotech News

Tonix Pharmaceuticals to Participate in Two Investor Conferences in May

Tonix Pharmaceuticals (TNXP)Tonix PharmaceuticalsCompany update

TNXP (TNXP) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is tnxp.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

TNXPTonix Pharmaceuticals2026-06-29 11:25 EST

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)

TNXPTonix Pharmaceuticals2026-08-05 11:00 EST

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

ECORelectroCore2026-08-03 12:00 EST

electroCore to Participate in Upcoming Investor Conferences

HRMYHarmony Biosciences2026-05-27 12:05 EST

Harmony Biosciences to Participate in Upcoming Investor Conferences

ANNXAnnexon, Inc.2026-05-27 12:00 EST

Annexon to Participate in Upcoming June Investor Conferences

AXSMAxsome2026-05-27 11:00 EST

Axsome Therapeutics to Participate in Upcoming Investor Conferences

NBIXNeurocrine Biosciences2026-05-26 20:01 EST

Neurocrine Biosciences to Present at Upcoming Investor Conferences in June

CGTXCognition Therapeutics2026-06-01 11:30 EST

Cognition Therapeutics Participating in Upcoming Investor Conferences

RVPHReviva Pharmaceuticals2026-05-18 12:00 EST

Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase

ABOSAcumen Pharmaceuticals2026-06-16 11:30 EST

Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease

View all latest news

Tonix Pharmaceuticals

Commercial Fibromyalgia Franchise Tonix Pharmaceuticals is a commercial-stage biopharmaceutical company centered on TONMYA, a bedtime treatment for fibromyalgia. The product is intended to address nonrestorative sleep and other core features of the disease and represents the company's principal commercial franchise. Infectious-Disease...

Recent company news

TNXPTonix Pharmaceuticals2026-08-05 11:00 EST

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

TNXPTonix Pharmaceuticals2026-08-03 11:00 EST

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

TNXPTonix Pharmaceuticals2026-07-27 11:00 EST

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

TNXPTonix Pharmaceuticals2026-07-15 13:05 EST

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

TNXPTonix Pharmaceuticals2026-07-13 11:00 EST

Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®

Stock data

Close
11.65 USD
Market cap
186.83M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States